Innovation Showcase Friday lunchtime
The cell and gene therapy market has experienced an immense growth driven by the recent landmark approvals of therapies such as Novartis’ Kymriah, Kite/Gilead’s Yescarta and Spark’s Luxturna. A pipeline filled with promising pre-clinical and clinical candidates provides confidence that the cell and gene therapy field is becoming a key player in the pharmaceutical world. While the products are showing remarkable therapeutic efficacy, there is an emerging need for flexible and robust manufacturing platforms capable of both scaling up and scaling out, while maintaining control over the cell processing parameters to achieve consistent product of highest quality and safety. Further production of these therapies at a large scale will be key to bringing these therapies to patients globally. Production costs of cell and gene therapies remain another obstacle the field has been facing; this is mostly driven by manual processing, manufacturing footprint requirements and expensive raw materials and testing. Automation represents itself as a potential solution for at least some of these challenges and therefore driving commercial viability of these therapies. During this session we will outline the specific challenges development and manufacturing of these ground breaking therapies are facing and how innovative platforms may help overcome some of the issues faced by the industry.
Innovation Showcase: Lonza
11:30 - 12:30
11:30 - 12:30
Innovation Showcase: INDUSTRIALIZATION OF CELL & GENE THERAPY MANUFACTURING- FROM CONCEPT TO PATIENTS - Lonza and guest from Semma Therapeutics